Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial
Condition: COVID-19 Interventions: Biological: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells); Biological: Placebo Sponsors: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.; Hunan Provincial Center for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Centers for Disease Control and Prevention (CDC) | Clinical Trials | Coronavirus | Covid Vaccine | COVID-19 | Research | Vaccines